Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 237

1.

Standardized Outcomes in Nephrology-Glomerular Disease (SONG-GD): establishing a core outcome set for trials in patients with glomerular disease.

Carter SA, Lightstone L, Cattran D, Bagga A, Barbour SJ, Barratt J, Boletis J, Caster D, Coppo R, Fervenza FC, Floege J, Hladunewich M, Hogan JJ, Kitching AR, Lafayette R, Malvar A, Radhakrishnan J, Rovin BH, Zhang H, Gutman T, Howell M, Logeman C, Shen JI, Teixeira-Pinto A, Alexander SI, Cho Y, Craig JC, Harris D, Johnson DW, Kerr PG, Ryan J, Viecelli AK, Wang AY, Wilkie M, Scholes-Robertson N, Tong A; SONG-GD Initiative.

Kidney Int. 2019 Jun;95(6):1280-1283. doi: 10.1016/j.kint.2019.01.047. No abstract available.

PMID:
31122702
2.

Exostosin 1/Exostosin 2-Associated Membranous Nephropathy.

Sethi S, Madden BJ, Debiec H, Charlesworth MC, Gross L, Ravindran A, Hummel AM, Specks U, Fervenza FC, Ronco P.

J Am Soc Nephrol. 2019 Jun;30(6):1123-1136. doi: 10.1681/ASN.2018080852. Epub 2019 May 6.

PMID:
31061139
3.

Serum levels of DNAJB9 are elevated in fibrillary glomerulonephritis patients.

Nasr SH, Dasari S, Lieske JC, Benson LM, Vanderboom PM, Holtz-Heppelmann CJ, Giesen CD, Snyder MR, Erickson SB, Fervenza FC, Leung N, Kurtin PJ, Alexander MP.

Kidney Int. 2019 May;95(5):1269-1272. doi: 10.1016/j.kint.2019.01.024. Epub 2019 Mar 1.

PMID:
31010480
4.

Open-Label Clinical Trials of Oral Pulse Dexamethasone for Adults with Idiopathic Nephrotic Syndrome.

Cho ME, Branton MH, Smith DA, Bartlett L, Howard L, Reynolds JC, Rosenstein D, Sethi S, Nava MB, Barisoni L, Fervenza FC, Kopp JB.

Am J Nephrol. 2019;49(5):377-385. doi: 10.1159/000497064. Epub 2019 Apr 9.

PMID:
30965344
5.

Editorial: a new era in anti-neutrophil cytoplasmic antibody vasculitis.

Fouque D, Fervenza FC.

Nephrol Dial Transplant. 2019 Mar 1;34(3):379-381. doi: 10.1093/ndt/gfz002. No abstract available.

PMID:
30834449
6.

Renal biopsy findings in patients with extreme obesity: more heterogeneous than you think.

Fervenza FC, Sethi S.

Kidney Int. 2019 Mar;95(3):495-498. doi: 10.1016/j.kint.2018.12.008.

PMID:
30784658
7.

Noninvasive diagnosis of primary membranous nephropathy using phospholipase A2 receptor antibodies.

Bobart SA, De Vriese AS, Pawar AS, Zand L, Sethi S, Giesen C, Lieske JC, Fervenza FC.

Kidney Int. 2019 Feb;95(2):429-438. doi: 10.1016/j.kint.2018.10.021.

PMID:
30665573
8.

Publisher Correction: The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0102-7.

PMID:
30568288
9.

The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.

Leung N, Bridoux F, Batuman V, Chaidos A, Cockwell P, D'Agati VD, Dispenzieri A, Fervenza FC, Fermand JP, Gibbs S, Gillmore JD, Herrera GA, Jaccard A, Jevremovic D, Kastritis E, Kukreti V, Kyle RA, Lachmann HJ, Larsen CP, Ludwig H, Markowitz GS, Merlini G, Mollee P, Picken MM, Rajkumar VS, Royal V, Sanders PW, Sethi S, Venner CP, Voorhees PM, Wechalekar AD, Weiss BM, Nasr SH.

Nat Rev Nephrol. 2019 Jan;15(1):45-59. doi: 10.1038/s41581-018-0077-4. Review. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30510265
10.

CKD Due to a Novel Mitochondrial DNA Mutation: A Case Report.

Fervenza FC, Gavrilova RH, Nasr SH, Irazabal MV, Nath KA.

Am J Kidney Dis. 2019 Feb;73(2):273-277. doi: 10.1053/j.ajkd.2018.06.032. Epub 2018 Oct 8.

PMID:
30309714
11.

Rituximab Exhibits Altered Pharmacokinetics in Patients With Membranous Nephropathy.

Fogueri U, Cheungapasitporn W, Bourne D, Fervenza FC, Joy MS.

Ann Pharmacother. 2019 Apr;53(4):357-363. doi: 10.1177/1060028018803587. Epub 2018 Oct 8.

PMID:
30293439
12.

Diagnostic Utility of Complement Serology for Atypical Hemolytic Uremic Syndrome.

Sridharan M, Go RS, Abraham RS, Fervenza FC, Sethi S, Bryant SC, Spears GM, Murray DL, Willrich MAV.

Mayo Clin Proc. 2018 Oct;93(10):1351-1362. doi: 10.1016/j.mayocp.2018.07.008.

PMID:
30286829
13.

The authors reply.

Ravindran A, Fervenza FC, Smith RJH, Sethi S.

Kidney Int. 2018 Sep;94(3):632-633. doi: 10.1016/j.kint.2018.06.002. No abstract available.

PMID:
30143071
14.

Standardized classification and reporting of glomerulonephritis.

Sethi S, Fervenza FC.

Nephrol Dial Transplant. 2019 Feb 1;34(2):193-199. doi: 10.1093/ndt/gfy220.

PMID:
30124958
15.

Incidence, prevalence, mortality and chronic renal damage of anti-neutrophil cytoplasmic antibody-associated glomerulonephritis in a 20-year population-based cohort.

Berti A, Cornec-Le Gall E, Cornec D, Casal Moura M, Matteson EL, Crowson CS, Ravindran A, Sethi S, Fervenza FC, Specks U.

Nephrol Dial Transplant. 2018 Aug 8. doi: 10.1093/ndt/gfy250. [Epub ahead of print]

PMID:
30102330
16.

C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.

Ravindran A, Fervenza FC, Smith RJH, De Vriese AS, Sethi S.

Mayo Clin Proc. 2018 Aug;93(8):991-1008. doi: 10.1016/j.mayocp.2018.05.019.

17.

Cryoglobulinaemia.

Roccatello D, Saadoun D, Ramos-Casals M, Tzioufas AG, Fervenza FC, Cacoub P, Zignego AL, Ferri C.

Nat Rev Dis Primers. 2018 Aug 2;4(1):11. doi: 10.1038/s41572-018-0009-4. Review.

18.

The impact of eculizumab on routine complement assays.

Willrich MAV, Andreguetto BD, Sridharan M, Fervenza FC, Tostrud LJ, Ladwig PM, Rivard AM, Hetrick MD, Olson RN, Bryant SC, Snyder MR, Murray DL.

J Immunol Methods. 2018 Sep;460:63-71. doi: 10.1016/j.jim.2018.06.010. Epub 2018 Jun 20.

PMID:
29935209
19.

Congophilic Fibrillary Glomerulonephritis: A Case Series.

Alexander MP, Dasari S, Vrana JA, Riopel J, Valeri AM, Markowitz GS, Hever A, Bijol V, Larsen CP, Cornell LD, Fidler ME, Said SM, Sethi S, Herrera Hernandez LP, Grande JP, Erickson SB, Fervenza FC, Leung N, Kurtin PJ, Nasr SH.

Am J Kidney Dis. 2018 Sep;72(3):325-336. doi: 10.1053/j.ajkd.2018.03.017. Epub 2018 Jun 14.

PMID:
29866458
20.

Membranous Nephropathy: Approaches to Treatment.

Bomback AS, Fervenza FC.

Am J Nephrol. 2018;47 Suppl 1:30-42. doi: 10.1159/000481635. Epub 2018 May 31.

21.

Kidney Involvement of Patients with Waldenström Macroglobulinemia and Other IgM-Producing B Cell Lymphoproliferative Disorders.

Higgins L, Nasr SH, Said SM, Kapoor P, Dingli D, King RL, Rajkumar SV, Kyle RA, Kourelis T, Gertz MA, Dispenzieri A, Lacy MQ, Buadi FK, Ansell SM, Gonsalves WI, Thompson CA, Fervenza FC, Zand L, Hwa YL, Jevremovic D, Shi M, Leung N.

Clin J Am Soc Nephrol. 2018 Jul 6;13(7):1037-1046. doi: 10.2215/CJN.13041117. Epub 2018 May 30.

PMID:
29848505
22.

C3 glomerulopathy associated with monoclonal Ig is a distinct subtype.

Ravindran A, Fervenza FC, Smith RJH, Sethi S.

Kidney Int. 2018 Jul;94(1):178-186. doi: 10.1016/j.kint.2018.01.037. Epub 2018 May 3. Erratum in: Kidney Int. 2018 Nov;94(5):1025.

PMID:
29729982
23.

Proliferative glomerulonephritis with monoclonal immunoglobulin G deposits is associated with high rate of early recurrence in the allograft.

Said SM, Cosio FG, Valeri AM, Leung N, Sethi S, Salameh H, Cornell LD, Fidler ME, Alexander MP, Fervenza FC, Drosou ME, Zhang D, D'Agati VD, Nasr SH.

Kidney Int. 2018 Jul;94(1):159-169. doi: 10.1016/j.kint.2018.01.028. Epub 2018 Apr 30.

PMID:
29716794
24.

Brief Report: Circulating Cytokine Profiles and Antineutrophil Cytoplasmic Antibody Specificity in Patients With Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Berti A, Warner R, Johnson K, Cornec D, Schroeder D, Kabat B, Langford CA, Hoffman GS, Fervenza FC, Kallenberg CGM, Seo P, Spiera R, St Clair EW, Brunetta P, Stone JH, Merkel PA, Specks U, Monach PA; RAVE-ITN Research Group.

Arthritis Rheumatol. 2018 Jul;70(7):1114-1121. doi: 10.1002/art.40471. Epub 2018 May 7.

PMID:
29693324
25.

Clinical and pathological phenotype of genetic causes of focal segmental glomerulosclerosis in adults.

Lepori N, Zand L, Sethi S, Fernandez-Juarez G, Fervenza FC.

Clin Kidney J. 2018 Apr;11(2):179-190. doi: 10.1093/ckj/sfx143. Epub 2018 Jan 9.

26.

Disease Progression and End-Stage Renal Disease in Diverse Glomerulopathies.

Nath KA, Fervenza FC.

Mayo Clin Proc. 2018 Feb;93(2):133-135. doi: 10.1016/j.mayocp.2017.12.018. Epub 2018 Jan 24. No abstract available.

PMID:
29395349
27.

The Utility of Urinalysis in Determining the Risk of Renal Relapse in ANCA-Associated Vasculitis.

Rhee RL, Davis JC, Ding L, Fervenza FC, Hoffman GS, Kallenberg CGM, Langford CA, McCune WJ, Monach PA, Seo P, Spiera R, St Clair EW, Specks U, Stone JH, Merkel PA.

Clin J Am Soc Nephrol. 2018 Feb 7;13(2):251-257. doi: 10.2215/CJN.04160417. Epub 2018 Jan 25.

28.

DNAJB9 Is a Specific Immunohistochemical Marker for Fibrillary Glomerulonephritis.

Nasr SH, Vrana JA, Dasari S, Bridoux F, Fidler ME, Kaaki S, Quellard N, Rinsant A, Goujon JM, Sethi S, Fervenza FC, Cornell LD, Said SM, McPhail ED, Herrera Hernandez LP, Grande JP, Hogan MC, Lieske JC, Leung N, Kurtin PJ, Alexander MP.

Kidney Int Rep. 2017 Aug 8;3(1):56-64. doi: 10.1016/j.ekir.2017.07.017. eCollection 2018 Jan.

29.

Differentiating Primary, Genetic, and Secondary FSGS in Adults: A Clinicopathologic Approach.

De Vriese AS, Sethi S, Nath KA, Glassock RJ, Fervenza FC.

J Am Soc Nephrol. 2018 Mar;29(3):759-774. doi: 10.1681/ASN.2017090958. Epub 2018 Jan 10.

30.

Global glomerulosclerosis with nephrotic syndrome; the clinical importance of age adjustment.

Hommos MS, Zeng C, Liu Z, Troost JP, Rosenberg AZ, Palmer M, Kremers WK, Cornell LD, Fervenza FC, Barisoni L, Rule AD.

Kidney Int. 2018 May;93(5):1175-1182. doi: 10.1016/j.kint.2017.09.028. Epub 2017 Dec 19.

31.

A Phase 2, Double-Blind, Placebo-Controlled, Randomized Study of Fresolimumab in Patients With Steroid-Resistant Primary Focal Segmental Glomerulosclerosis.

Vincenti F, Fervenza FC, Campbell KN, Diaz M, Gesualdo L, Nelson P, Praga M, Radhakrishnan J, Sellin L, Singh A, Thornley-Brown D, Veronese FV, Accomando B, Engstrand S, Ledbetter S, Lin J, Neylan J, Tumlin J; Focal Segmental Glomerulosclerosis Study Group.

Kidney Int Rep. 2017 Apr 7;2(5):800-810. doi: 10.1016/j.ekir.2017.03.011. eCollection 2017 Sep.

32.

High-dose melphalan and autologous hematopoietic stem cell transplant in patient with C3 glomerulonephritis associated with monoclonal gammopathy
.

Lepori N, Cheungpasitporn W, Sethi S, Murray D, Kumar S, Leung N, Giridhar KV, Fervenza FC.

Clin Nephrol. 2018 Apr;89(4):291-299. doi: 10.5414/CN109300.

PMID:
29249234
33.

The Incidence of Primary vs Secondary Focal Segmental Glomerulosclerosis: A Clinicopathologic Study.

Hommos MS, De Vriese AS, Alexander MP, Sethi S, Vaughan L, Zand L, Bharucha K, Lepori N, Rule AD, Fervenza FC.

Mayo Clin Proc. 2017 Dec;92(12):1772-1781. doi: 10.1016/j.mayocp.2017.09.011. Epub 2017 Oct 27.

34.

Interstitial Immunostaining and Renal Outcomes in Antineutrophil Cytoplasmic Antibody-Associated Glomerulonephritis.

Geetha D, Sethi S, De Vriese AS, Specks U, Kallenberg CGM, Lim N, Spiera R, St Clair EW, Merkel PA, Seo P, Monach PA, Lepori N, Fessler BJ, Langford CA, Hoffman GS, Sharma R, Stone JH, Fervenza FC; RAVE-ITN Research Group.

Am J Nephrol. 2017;46(3):231-238. doi: 10.1159/000480443. Epub 2017 Sep 8.

PMID:
28881339
35.

Treatment of primary membranous nephropathy: where are we now?

Angioi A, Lepori N, López AC, Sethi S, Fervenza FC, Pani A.

J Nephrol. 2018 Aug;31(4):489-502. doi: 10.1007/s40620-017-0427-5. Epub 2017 Sep 5. Review.

PMID:
28875476
36.

Familial antiglomerular basement membrane disease in zero human leukocyte antigen mismatch siblings
.

Angioi A, Cheungpasitporn W, Sethi S, De Vriese AS, Lepori N, Schwab TR, Fervenza FC.

Clin Nephrol. 2017 Nov;88(11):277-283. doi: 10.5414/CN109206.

PMID:
28853702
37.

C4 Nephritic Factors in C3 Glomerulopathy: A Case Series.

Zhang Y, Meyer NC, Fervenza FC, Lau W, Keenan A, Cara-Fuentes G, Shao D, Akber A, Fremeaux-Bacchi V, Sethi S, Nester CM, Smith RJH.

Am J Kidney Dis. 2017 Dec;70(6):834-843. doi: 10.1053/j.ajkd.2017.07.004. Epub 2017 Aug 24.

38.

Persistent Microscopic Hematuria as a Risk Factor for Progression of IgA Nephropathy: New Floodlight on a Nearly Forgotten Biomarker.

Coppo R, Fervenza FC.

J Am Soc Nephrol. 2017 Oct;28(10):2831-2834. doi: 10.1681/ASN.2017060639. Epub 2017 Jul 24. No abstract available.

39.

The Authors Reply.

Ravindran A, Go RS, Fervenza FC, Sethi S.

Kidney Int. 2017 Aug;92(2):517. doi: 10.1016/j.kint.2017.04.040. No abstract available.

PMID:
28709607
40.

Treatment of membranous nephropathy: time for a paradigm shift.

Ruggenenti P, Fervenza FC, Remuzzi G.

Nat Rev Nephrol. 2017 Sep;13(9):563-579. doi: 10.1038/nrneph.2017.92. Epub 2017 Jul 3. Review.

PMID:
28669992
41.

C3 glomerulonephritis with a severe crescentic phenotype.

Ravindran A, Fervenza FC, Smith RJH, Sethi S.

Pediatr Nephrol. 2017 Sep;32(9):1625-1633. doi: 10.1007/s00467-017-3702-8. Epub 2017 Jun 7.

PMID:
28593446
42.

Non-ischemic cardiomyopathy after rituximab treatment for membranous nephropathy.

Cheungpasitporn W, Kopecky SL, Specks U, Bharucha K, Fervenza FC.

J Renal Inj Prev. 2016 Nov 2;6(1):18-25. doi: 10.15171/jrip.2017.04. eCollection 2017.

43.

What are we missing in the clinical trials of focal segmental glomerulosclerosis?

Zand L, Glassock RJ, De Vriese AS, Sethi S, Fervenza FC.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i14-i21. doi: 10.1093/ndt/gfw324. Review.

PMID:
28391338
44.

Complement activation in pauci-immune necrotizing and crescentic glomerulonephritis: results of a proteomic analysis.

Sethi S, Zand L, De Vriese AS, Specks U, Vrana JA, Kanwar S, Kurtin P, Theis JD, Angioi A, Cornell L, Fervenza FC.

Nephrol Dial Transplant. 2017 Jan 1;32(suppl_1):i139-i145. doi: 10.1093/ndt/gfw299.

PMID:
28391334
45.

A proposal for standardized grading of chronic changes in native kidney biopsy specimens.

Sethi S, D'Agati VD, Nast CC, Fogo AB, De Vriese AS, Markowitz GS, Glassock RJ, Fervenza FC, Seshan SV, Rule A, Racusen LC, Radhakrishnan J, Winearls CG, Appel GB, Bajema IM, Chang A, Colvin RB, Cook HT, Hariharan S, Herrera Hernandez LP, Kambham N, Mengel M, Nath KA, Rennke HG, Ronco P, Rovin BH, Haas M.

Kidney Int. 2017 Apr;91(4):787-789. doi: 10.1016/j.kint.2017.01.002.

PMID:
28314581
46.

Immunoglobulin (Ig)M antibodies to proteinase 3 in granulomatosis with polyangiitis and microscopic polyangiitis.

Clain JM, Hummel AM, Stone JH, Fervenza FC, Hoffman GS, Kallenberg CG, Langford CA, McCune WJ, Merkel PA, Monach PA, Seo P, Spiera RF, St Clair EW, Ytterberg SR, Specks U; WGET and RAVE-ITN Research Groups.

Clin Exp Immunol. 2017 Apr;188(1):174-181. doi: 10.1111/cei.12925. Epub 2017 Feb 7.

47.

Thrombotic microangiopathy associated with monoclonal gammopathy.

Ravindran A, Go RS, Fervenza FC, Sethi S.

Kidney Int. 2017 Mar;91(3):691-698. doi: 10.1016/j.kint.2016.09.045. Epub 2016 Dec 18.

PMID:
27998645
48.

Atypical hemolytic uremic syndrome and C3 glomerulopathy: conclusions from a "Kidney Disease: Improving Global Outcomes" (KDIGO) Controversies Conference.

Goodship TH, Cook HT, Fakhouri F, Fervenza FC, Frémeaux-Bacchi V, Kavanagh D, Nester CM, Noris M, Pickering MC, Rodríguez de Córdoba S, Roumenina LT, Sethi S, Smith RJ; Conference Participants.

Kidney Int. 2017 Mar;91(3):539-551. doi: 10.1016/j.kint.2016.10.005. Epub 2016 Dec 16.

49.

A Randomized, Controlled Trial of Rituximab in IgA Nephropathy with Proteinuria and Renal Dysfunction.

Lafayette RA, Canetta PA, Rovin BH, Appel GB, Novak J, Nath KA, Sethi S, Tumlin JA, Mehta K, Hogan M, Erickson S, Julian BA, Leung N, Enders FT, Brown R, Knoppova B, Hall S, Fervenza FC.

J Am Soc Nephrol. 2017 Apr;28(4):1306-1313. doi: 10.1681/ASN.2016060640. Epub 2016 Nov 7.

50.

A Proposal for a Serology-Based Approach to Membranous Nephropathy.

De Vriese AS, Glassock RJ, Nath KA, Sethi S, Fervenza FC.

J Am Soc Nephrol. 2017 Feb;28(2):421-430. doi: 10.1681/ASN.2016070776. Epub 2016 Oct 24. Review.

Supplemental Content

Loading ...
Support Center